JP2012095657A - Jnkシグナル伝達経路の細胞透過性ペプチド阻害剤 - Google Patents
Jnkシグナル伝達経路の細胞透過性ペプチド阻害剤 Download PDFInfo
- Publication number
- JP2012095657A JP2012095657A JP2012000381A JP2012000381A JP2012095657A JP 2012095657 A JP2012095657 A JP 2012095657A JP 2012000381 A JP2012000381 A JP 2012000381A JP 2012000381 A JP2012000381 A JP 2012000381A JP 2012095657 A JP2012095657 A JP 2012095657A
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- peptide
- jnk
- jnk inhibitor
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract description 23
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 201
- 230000019491 signal transduction Effects 0.000 title abstract description 10
- 239000012825 JNK inhibitor Substances 0.000 claims abstract description 152
- 229940118135 JNK inhibitor Drugs 0.000 claims abstract description 150
- 108091006116 chimeric peptides Proteins 0.000 claims abstract description 131
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 claims abstract description 108
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 82
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 68
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 68
- 230000007310 pathophysiology Effects 0.000 claims abstract description 19
- 210000004027 cell Anatomy 0.000 claims description 159
- 150000001413 amino acids Chemical class 0.000 claims description 80
- 230000032258 transport Effects 0.000 claims description 75
- 238000000034 method Methods 0.000 claims description 67
- 239000012634 fragment Substances 0.000 claims description 62
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 56
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 51
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 41
- 230000000694 effects Effects 0.000 claims description 37
- 201000010099 disease Diseases 0.000 claims description 34
- 230000014509 gene expression Effects 0.000 claims description 27
- 239000013598 vector Substances 0.000 claims description 27
- 102100023132 Transcription factor Jun Human genes 0.000 claims description 24
- 125000000539 amino acid group Chemical group 0.000 claims description 24
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 claims description 22
- 108020004414 DNA Proteins 0.000 claims description 21
- 230000001575 pathological effect Effects 0.000 claims description 21
- 230000004913 activation Effects 0.000 claims description 18
- 239000008196 pharmacological composition Substances 0.000 claims description 18
- 229920001184 polypeptide Polymers 0.000 claims description 18
- 238000011282 treatment Methods 0.000 claims description 15
- 102100023033 Cyclic AMP-dependent transcription factor ATF-2 Human genes 0.000 claims description 14
- 101000974934 Homo sapiens Cyclic AMP-dependent transcription factor ATF-2 Proteins 0.000 claims description 14
- 101000997829 Homo sapiens Glial cell line-derived neurotrophic factor Proteins 0.000 claims description 14
- 108091023040 Transcription factor Proteins 0.000 claims description 13
- 102000040945 Transcription factor Human genes 0.000 claims description 13
- 230000006907 apoptotic process Effects 0.000 claims description 12
- 206010008118 cerebral infarction Diseases 0.000 claims description 12
- 208000028867 ischemia Diseases 0.000 claims description 12
- 230000002062 proliferating effect Effects 0.000 claims description 10
- 206010011878 Deafness Diseases 0.000 claims description 9
- 230000010370 hearing loss Effects 0.000 claims description 9
- 231100000888 hearing loss Toxicity 0.000 claims description 9
- 208000016354 hearing loss disease Diseases 0.000 claims description 9
- 238000001990 intravenous administration Methods 0.000 claims description 8
- 208000011580 syndromic disease Diseases 0.000 claims description 7
- 102000004127 Cytokines Human genes 0.000 claims description 6
- 108090000695 Cytokines Proteins 0.000 claims description 6
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 6
- 206010021143 Hypoxia Diseases 0.000 claims description 6
- 208000021642 Muscular disease Diseases 0.000 claims description 6
- 201000009623 Myopathy Diseases 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 206010063837 Reperfusion injury Diseases 0.000 claims description 6
- 208000037849 arterial hypertension Diseases 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 230000001413 cellular effect Effects 0.000 claims description 6
- 230000006378 damage Effects 0.000 claims description 6
- 230000007954 hypoxia Effects 0.000 claims description 6
- 230000005865 ionizing radiation Effects 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 230000003902 lesion Effects 0.000 claims description 5
- 230000003211 malignant effect Effects 0.000 claims description 5
- 230000035882 stress Effects 0.000 claims description 5
- 208000030507 AIDS Diseases 0.000 claims description 4
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims description 4
- 208000006029 Cardiomegaly Diseases 0.000 claims description 4
- 230000011748 cell maturation Effects 0.000 claims description 4
- 230000004700 cellular uptake Effects 0.000 claims description 4
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 4
- 210000002865 immune cell Anatomy 0.000 claims description 4
- 230000036039 immunity Effects 0.000 claims description 4
- 230000002757 inflammatory effect Effects 0.000 claims description 4
- 238000007912 intraperitoneal administration Methods 0.000 claims description 4
- 230000030648 nucleus localization Effects 0.000 claims description 4
- 238000001959 radiotherapy Methods 0.000 claims description 4
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 claims description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 3
- 208000011594 Autoinflammatory disease Diseases 0.000 claims description 3
- 208000027496 Behcet disease Diseases 0.000 claims description 3
- 208000009137 Behcet syndrome Diseases 0.000 claims description 3
- 208000016952 Ear injury Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 206010020843 Hyperthermia Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 241000721454 Pemphigus Species 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 3
- 206010040070 Septic Shock Diseases 0.000 claims description 3
- 206010047115 Vasculitis Diseases 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 210000000481 breast Anatomy 0.000 claims description 3
- 230000024245 cell differentiation Effects 0.000 claims description 3
- 229940044683 chemotherapy drug Drugs 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 238000000502 dialysis Methods 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 230000002496 gastric effect Effects 0.000 claims description 3
- 230000036031 hyperthermia Effects 0.000 claims description 3
- 230000002631 hypothermal effect Effects 0.000 claims description 3
- 208000026278 immune system disease Diseases 0.000 claims description 3
- 208000027866 inflammatory disease Diseases 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 210000003563 lymphoid tissue Anatomy 0.000 claims description 3
- 230000002107 myocardial effect Effects 0.000 claims description 3
- 208000031225 myocardial ischemia Diseases 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 3
- 230000006548 oncogenic transformation Effects 0.000 claims description 3
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims description 3
- 208000037803 restenosis Diseases 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 230000036303 septic shock Effects 0.000 claims description 3
- 201000002314 small intestine cancer Diseases 0.000 claims description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
- 206010020880 Hypertrophy Diseases 0.000 claims description 2
- 208000009956 adenocarcinoma Diseases 0.000 claims description 2
- 210000004204 blood vessel Anatomy 0.000 claims description 2
- 230000036210 malignancy Effects 0.000 claims description 2
- 230000003938 response to stress Effects 0.000 claims description 2
- 230000009291 secondary effect Effects 0.000 claims description 2
- FXYZDFSNBBOHTA-UHFFFAOYSA-N 2-[amino(morpholin-4-ium-4-ylidene)methyl]guanidine;chloride Chemical compound Cl.NC(N)=NC(=N)N1CCOCC1 FXYZDFSNBBOHTA-UHFFFAOYSA-N 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 102000019145 JUN kinase activity proteins Human genes 0.000 abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 4
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 abstract description 2
- 239000003909 protein kinase inhibitor Substances 0.000 abstract description 2
- 235000001014 amino acid Nutrition 0.000 description 82
- 229940024606 amino acid Drugs 0.000 description 79
- 108090000623 proteins and genes Proteins 0.000 description 52
- 235000018102 proteins Nutrition 0.000 description 30
- 102000004169 proteins and genes Human genes 0.000 description 30
- 150000008575 L-amino acids Chemical class 0.000 description 28
- 150000008574 D-amino acids Chemical class 0.000 description 23
- 230000027455 binding Effects 0.000 description 21
- 239000003431 cross linking reagent Substances 0.000 description 19
- 239000013604 expression vector Substances 0.000 description 19
- 239000000243 solution Substances 0.000 description 19
- 241000282414 Homo sapiens Species 0.000 description 15
- 230000005764 inhibitory process Effects 0.000 description 15
- 108091000080 Phosphotransferase Proteins 0.000 description 14
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 14
- 238000001727 in vivo Methods 0.000 description 14
- 102000020233 phosphotransferase Human genes 0.000 description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- 238000000338 in vitro Methods 0.000 description 13
- 230000004048 modification Effects 0.000 description 13
- 238000012986 modification Methods 0.000 description 13
- 230000026731 phosphorylation Effects 0.000 description 13
- 238000006366 phosphorylation reaction Methods 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 12
- 241000700159 Rattus Species 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- 238000012217 deletion Methods 0.000 description 12
- 230000037430 deletion Effects 0.000 description 12
- 230000004224 protection Effects 0.000 description 12
- 238000006467 substitution reaction Methods 0.000 description 12
- 239000011324 bead Substances 0.000 description 11
- 238000001415 gene therapy Methods 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 230000004927 fusion Effects 0.000 description 10
- 125000005647 linker group Chemical group 0.000 description 10
- 230000001105 regulatory effect Effects 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 230000008685 targeting Effects 0.000 description 10
- 101001046656 Homo sapiens C-Jun-amino-terminal kinase-interacting protein 2 Proteins 0.000 description 9
- 101000628949 Homo sapiens Mitogen-activated protein kinase 10 Proteins 0.000 description 9
- 102100026931 Mitogen-activated protein kinase 10 Human genes 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 201000006474 Brain Ischemia Diseases 0.000 description 8
- 102100022287 C-Jun-amino-terminal kinase-interacting protein 2 Human genes 0.000 description 8
- 206010008120 Cerebral ischaemia Diseases 0.000 description 8
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 8
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 8
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 8
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 8
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 8
- 241000700605 Viruses Species 0.000 description 8
- 238000007792 addition Methods 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 230000004071 biological effect Effects 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 239000005090 green fluorescent protein Substances 0.000 description 8
- 238000003018 immunoassay Methods 0.000 description 8
- 102000000589 Interleukin-1 Human genes 0.000 description 7
- 108010002352 Interleukin-1 Proteins 0.000 description 7
- 101710149951 Protein Tat Proteins 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 108020001507 fusion proteins Proteins 0.000 description 7
- 102000037865 fusion proteins Human genes 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 208000014674 injury Diseases 0.000 description 7
- 210000003657 middle cerebral artery Anatomy 0.000 description 7
- 210000005036 nerve Anatomy 0.000 description 7
- 230000000324 neuroprotective effect Effects 0.000 description 7
- 235000013930 proline Nutrition 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 239000004365 Protease Substances 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 230000030833 cell death Effects 0.000 description 6
- 210000000170 cell membrane Anatomy 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000004132 cross linking Methods 0.000 description 6
- 210000000805 cytoplasm Anatomy 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 6
- 230000005855 radiation Effects 0.000 description 6
- 230000002285 radioactive effect Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 230000008733 trauma Effects 0.000 description 6
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
- 241000972773 Aulopiformes Species 0.000 description 5
- 101000950669 Homo sapiens Mitogen-activated protein kinase 9 Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 description 5
- 108091005804 Peptidases Proteins 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 5
- 210000004408 hybridoma Anatomy 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 235000019515 salmon Nutrition 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 230000001052 transient effect Effects 0.000 description 5
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 4
- 239000004971 Cross linker Substances 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 229920001917 Ficoll Polymers 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 101000950695 Homo sapiens Mitogen-activated protein kinase 8 Proteins 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
- 102000018697 Membrane Proteins Human genes 0.000 description 4
- 108010052285 Membrane Proteins Proteins 0.000 description 4
- 102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 4
- 239000004473 Threonine Substances 0.000 description 4
- 239000012190 activator Substances 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 238000003016 alphascreen Methods 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 230000001640 apoptogenic effect Effects 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- SCMLRESZJCKCTC-KMYQRJGFSA-N gtpl8173 Chemical compound C12=CC=C(CSCC)C=C2C2=C(CNC3=O)C3=C3C4=CC(CSCC)=CC=C4N4C3=C2N1[C@]1(C)[C@@](O)(C(=O)OC)C[C@H]4O1 SCMLRESZJCKCTC-KMYQRJGFSA-N 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 230000010410 reperfusion Effects 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 125000006850 spacer group Chemical group 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 125000003396 thiol group Chemical group [H]S* 0.000 description 4
- 150000003573 thiols Chemical class 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 241000700198 Cavia Species 0.000 description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 3
- 102100023274 Dual specificity mitogen-activated protein kinase kinase 4 Human genes 0.000 description 3
- 102100023332 Dual specificity mitogen-activated protein kinase kinase 7 Human genes 0.000 description 3
- 101150033452 Elk1 gene Proteins 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 102100039556 Galectin-4 Human genes 0.000 description 3
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 101001115395 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 4 Proteins 0.000 description 3
- 101000624594 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 7 Proteins 0.000 description 3
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
- 206010061216 Infarction Diseases 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108010018525 NFATC Transcription Factors Proteins 0.000 description 3
- 102000002673 NFATC Transcription Factors Human genes 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 102000009097 Phosphorylases Human genes 0.000 description 3
- 108010073135 Phosphorylases Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 102000001253 Protein Kinase Human genes 0.000 description 3
- 101100287693 Rattus norvegicus Kcnh4 gene Proteins 0.000 description 3
- 101100287705 Rattus norvegicus Kcnh8 gene Proteins 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- HRMVIAFZYCCHGF-BMCUWHFPSA-N am111 peptide Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H]([C@H](C)O)C(=O)N1[C@H](CCC1)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCCN)C(=O)N1[C@H](CCC1)C(=O)N[C@H](CCCNC(N)=N)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@@H]1N(CCC1)C(=O)[C@@H](CCC(N)=O)NC(=O)[C@H](NC(=O)[C@@H]1N(CCC1)C(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CO)NC(=O)[C@@H](CCC(N)=O)NC(=O)[C@H](N)CC(O)=O)C(C)C)C1=CC=CC=C1 HRMVIAFZYCCHGF-BMCUWHFPSA-N 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000010382 chemical cross-linking Methods 0.000 description 3
- 239000013000 chemical inhibitor Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- -1 dimethyl Dimethyl adipimidate Chemical compound 0.000 description 3
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000007574 infarction Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 150000002632 lipids Chemical group 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000027405 negative regulation of phosphorylation Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000013615 primer Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000002864 sequence alignment Methods 0.000 description 3
- 210000003625 skull Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 2
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 2
- 102000055025 Adenosine deaminases Human genes 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 108700031308 Antennapedia Homeodomain Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108010060110 D-JNKI-1 Proteins 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 2
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 2
- 102100025390 Integrin beta-2 Human genes 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 108700041567 MDR Genes Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 101001135571 Mus musculus Tyrosine-protein phosphatase non-receptor type 2 Proteins 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 102000052812 Ornithine decarboxylases Human genes 0.000 description 2
- 108700005126 Ornithine decarboxylases Proteins 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 2
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 2
- 108010022394 Threonine synthase Proteins 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 239000013602 bacteriophage vector Substances 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000005460 biophysical method Methods 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000007910 cell fusion Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 238000012412 chemical coupling Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 238000005094 computer simulation Methods 0.000 description 2
- 230000001268 conjugating effect Effects 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000005786 degenerative changes Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 102000004419 dihydrofolate reductase Human genes 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 230000006353 environmental stress Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
- 238000000021 kinase assay Methods 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000004112 neuroprotection Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 230000002633 protecting effect Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000007790 scraping Methods 0.000 description 2
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 229940048086 sodium pyrophosphate Drugs 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000012916 structural analysis Methods 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 2
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Chemical group OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- LLXVXPPXELIDGQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)benzoate Chemical compound C=1C=CC(N2C(C=CC2=O)=O)=CC=1C(=O)ON1C(=O)CCC1=O LLXVXPPXELIDGQ-UHFFFAOYSA-N 0.000 description 1
- FXYPGCIGRDZWNR-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-[[3-(2,5-dioxopyrrolidin-1-yl)oxy-3-oxopropyl]disulfanyl]propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSCCC(=O)ON1C(=O)CCC1=O FXYPGCIGRDZWNR-UHFFFAOYSA-N 0.000 description 1
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- IVWWFWFVSWOTLP-YVZVNANGSA-N (3'as,4r,7'as)-2,2,2',2'-tetramethylspiro[1,3-dioxolane-4,6'-4,7a-dihydro-3ah-[1,3]dioxolo[4,5-c]pyran]-7'-one Chemical compound C([C@@H]1OC(O[C@@H]1C1=O)(C)C)O[C@]21COC(C)(C)O2 IVWWFWFVSWOTLP-YVZVNANGSA-N 0.000 description 1
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- VILFTWLXLYIEMV-UHFFFAOYSA-N 1,5-difluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC([N+]([O-])=O)=C(F)C=C1F VILFTWLXLYIEMV-UHFFFAOYSA-N 0.000 description 1
- VZZPYUKWXDLMGI-UHFFFAOYSA-N 1,6-diisothiocyanatohexane Chemical compound S=C=NCCCCCCN=C=S VZZPYUKWXDLMGI-UHFFFAOYSA-N 0.000 description 1
- DIYPCWKHSODVAP-UHFFFAOYSA-N 1-[3-(2,5-dioxopyrrol-1-yl)benzoyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1=CC=CC(N2C(C=CC2=O)=O)=C1 DIYPCWKHSODVAP-UHFFFAOYSA-N 0.000 description 1
- IPJGAEWUPXWFPL-UHFFFAOYSA-N 1-[3-(2,5-dioxopyrrol-1-yl)phenyl]pyrrole-2,5-dione Chemical compound O=C1C=CC(=O)N1C1=CC=CC(N2C(C=CC2=O)=O)=C1 IPJGAEWUPXWFPL-UHFFFAOYSA-N 0.000 description 1
- XQUPVDVFXZDTLT-UHFFFAOYSA-N 1-[4-[[4-(2,5-dioxopyrrol-1-yl)phenyl]methyl]phenyl]pyrrole-2,5-dione Chemical group O=C1C=CC(=O)N1C(C=C1)=CC=C1CC1=CC=C(N2C(C=CC2=O)=O)C=C1 XQUPVDVFXZDTLT-UHFFFAOYSA-N 0.000 description 1
- KHAWDEWNXJIVCJ-UHFFFAOYSA-N 1-fluoro-4-(4-fluoro-3-nitrophenyl)sulfonyl-2-nitrobenzene Chemical compound C1=C(F)C([N+](=O)[O-])=CC(S(=O)(=O)C=2C=C(C(F)=CC=2)[N+]([O-])=O)=C1 KHAWDEWNXJIVCJ-UHFFFAOYSA-N 0.000 description 1
- ZETXHVRPKUXQIT-UHFFFAOYSA-N 1-methyl-4-phenylpiperidine Chemical compound C1CN(C)CCC1C1=CC=CC=C1 ZETXHVRPKUXQIT-UHFFFAOYSA-N 0.000 description 1
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 1
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
- 150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- RLFPCLMBTQOMLI-UHFFFAOYSA-N 2-iodo-n-[2-[(2-iodoacetyl)amino]ethyl]acetamide Chemical compound ICC(=O)NCCNC(=O)CI RLFPCLMBTQOMLI-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-L 4-nitrophenyl phosphate(2-) Chemical compound [O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-L 0.000 description 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 101150016699 AFT2 gene Proteins 0.000 description 1
- 241000487918 Acacia argyrodendron Species 0.000 description 1
- 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102100022749 Aminopeptidase N Human genes 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000011814 C57BL/6N mouse Methods 0.000 description 1
- 102100024217 CAMPATH-1 antigen Human genes 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 108010065524 CD52 Antigen Proteins 0.000 description 1
- 102100037904 CD9 antigen Human genes 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 description 1
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 102100032768 Complement receptor type 2 Human genes 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 206010073306 Exposure to radiation Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 239000005057 Hexamethylene diisocyanate Substances 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101001046660 Homo sapiens C-Jun-amino-terminal kinase-interacting protein 1 Proteins 0.000 description 1
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 1
- 101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 1
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 description 1
- 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 1
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 description 1
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 description 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 description 1
- 101000652736 Homo sapiens Transgelin Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 206010060840 Ischaemic cerebral infarction Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 102100039564 Leukosialin Human genes 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108010068304 MAP Kinase Kinase 4 Proteins 0.000 description 1
- 102000002569 MAP Kinase Kinase 4 Human genes 0.000 description 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 1
- 102100025136 Macrosialin Human genes 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 108700027648 Mitogen-Activated Protein Kinase 8 Proteins 0.000 description 1
- 108700027653 Mitogen-Activated Protein Kinase 9 Proteins 0.000 description 1
- 101710107068 Myelin basic protein Proteins 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 102100035286 N-acetyl-D-glucosamine kinase Human genes 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- 108090000028 Neprilysin Proteins 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- 102100027584 Protein c-Fos Human genes 0.000 description 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 101100445383 Rattus norvegicus Ephb1 gene Proteins 0.000 description 1
- 101100341613 Rattus norvegicus Mapk8ip1 gene Proteins 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 102100038081 Signal transducer CD24 Human genes 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 102100027208 T-cell antigen CD7 Human genes 0.000 description 1
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 description 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
- 101710192266 Tegument protein VP22 Proteins 0.000 description 1
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 1
- 102100031013 Transgelin Human genes 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- ZHAFUINZIZIXFC-UHFFFAOYSA-N [9-(dimethylamino)-10-methylbenzo[a]phenoxazin-5-ylidene]azanium;chloride Chemical compound [Cl-].O1C2=CC(=[NH2+])C3=CC=CC=C3C2=NC2=C1C=C(N(C)C)C(C)=C2 ZHAFUINZIZIXFC-UHFFFAOYSA-N 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000008649 adaptation response Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000007818 agglutination assay Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Natural products C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000009141 biological interaction Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- BMLSTPRTEKLIPM-UHFFFAOYSA-I calcium;potassium;disodium;hydrogen carbonate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].OC([O-])=O BMLSTPRTEKLIPM-UHFFFAOYSA-I 0.000 description 1
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 210000004004 carotid artery internal Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 210000004298 cerebral vein Anatomy 0.000 description 1
- 235000011222 chang cao shi Nutrition 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 210000003618 cortical neuron Anatomy 0.000 description 1
- 239000013601 cosmid vector Substances 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000007821 culture assay Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000009297 electrocoagulation Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000002253 embryonic cardiomyocyte Anatomy 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000011556 gerbil model Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 230000005283 ground state Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- RRAMGCGOFNQTLD-UHFFFAOYSA-N hexamethylene diisocyanate Chemical compound O=C=NCCCCCCN=C=O RRAMGCGOFNQTLD-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 201000008298 histiocytosis Diseases 0.000 description 1
- 102000054579 human MAPK8IP1 Human genes 0.000 description 1
- 102000056438 human MAPK8IP2 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000002134 immunopathologic effect Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000000976 ink Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 238000007834 ligase chain reaction Methods 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000009061 membrane transport Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- NIQQIJXGUZVEBB-UHFFFAOYSA-N methanol;propan-2-one Chemical compound OC.CC(C)=O NIQQIJXGUZVEBB-UHFFFAOYSA-N 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000025308 nuclear transport Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 108010079892 phosphoglycerol kinase Proteins 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical compound N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920003192 poly(bis maleimide) Polymers 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000009396 radiation induced apoptosis Effects 0.000 description 1
- 230000004223 radioprotective effect Effects 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009703 regulation of cell differentiation Effects 0.000 description 1
- 230000025053 regulation of cell proliferation Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 206010073373 small intestine adenocarcinoma Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- VUFNRPJNRFOTGK-UHFFFAOYSA-M sodium;1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 VUFNRPJNRFOTGK-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 210000003594 spinal ganglia Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 1
- 230000004938 stress stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000012622 synthetic inhibitor Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 210000000966 temporal muscle Anatomy 0.000 description 1
- ATGUDZODTABURZ-UHFFFAOYSA-N thiolan-2-ylideneazanium;chloride Chemical compound Cl.N=C1CCCS1 ATGUDZODTABURZ-UHFFFAOYSA-N 0.000 description 1
- 125000000464 thioxo group Chemical group S=* 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000009751 type B pancreatic cell apoptotic process Effects 0.000 description 1
- 231100000402 unacceptable toxicity Toxicity 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 210000000216 zygoma Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16371—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
Abstract
【解決手段】本発明は、タンパク質キナーゼ阻害剤に関し、より具体的にはタンパク質キナーゼc‐Junアミノ末端キナーゼの阻害剤に関する。さらに、本発明は、JNK阻害剤配列、キメラペプチド、およびそれらをコードする核酸、ならびにJNKのシグナル伝達に関連する病態生理を治療するための薬理学的組成物を提供する。
【選択図】図1
Description
VQPFLNLTTPRKPR‐Xn a‐Xn b‐RRRQRRKKRG、あるいは、DQSRPVQPFLNLTTPRKP‐Xn a‐Xn b‐RRRQRRKKRG、DQSRPVQPFLNLTTPRK‐Xn a‐Xn b‐RRRQRRKKRG、DQSRPVQPFLNLTTPR‐Xn a‐Xn b‐RRRQRRKKRG、DQSRPVQPFLNLTTP‐Xn a‐Xn b‐RRRQRRKKRG、DQSRPVQPFLNLTT‐Xn a‐Xn b‐RRRQRRKKRG、あるいは、QSRPVQPFLNLTTPRKP‐Xn a‐Xn b‐RRRQRRKKRG、SRPVQPFLNLTTPRKP‐Xn a‐Xn b‐RRRQRRKKRG、SRPVQPFLNLTTPRK‐Xn a‐Xn b‐RRRQRRKKRG、RPVQPFLNLTTPRKP‐Xn a‐Xn b‐RRRQRRKKRG、RPVQPFLNLTTPRK‐Xn a‐Xn b‐RRRQRRKKRG、あるいは、PVQPFLNLTTP‐Xn a‐Xn b‐RRRQRRKKRG。第1ドメインの末端のみにおいて削除が起こっている好ましい実施の形態は、QSRPVQPFLNLTTPRKPR‐Xn a‐Xn b‐RRRQRRKKR、QSRPVQPFLNLTTPRKPR‐Xn a‐Xn b‐RRRQRRKK、QSRPVQPFLNLTTPRKPR‐Xn a‐Xn b‐RRQRRKKRG、QSRPVQPFLNLTTPRKPR‐Xn a‐Xn b‐RQRRKKRG、QSRPVQPFLNLTTPRKPR‐Xn a‐Xn b‐RRQRRKKR、QSRPVQPFLNLTTPRKPR‐Xn a‐Xn b‐RQRRKKR、QSRPVQPFLNLTTPRKPR‐Xn a‐Xn b‐RQRRKKである。
第1ドメインおよび第2ドメインにおいて削除が起こっている組み合わせは、例えば、それぞれ、QSRPVQPFLNLTTPRKPR‐Xn a‐Xn b‐RRRQRRKKR、SRPVQPFLNLTTPRKPR‐Xn a‐Xn b‐RRRQRRKKR、RPVQPFLNLTTPRKPR‐Xn a‐Xn b‐RRRQRRKKR、PVQPFLNLTTPRKPR‐Xn a‐Xn b‐RRRQRRKKR、または、VQPFLNLTTPRKPR‐Xn a‐Xn b‐RRRQRRKKR、あるいは、それぞれ、DQSRPVQPFLNLTTPRKP‐Xn a‐Xn b‐RRRQRRKKR、DQSRPVQPFLNLTTPRK‐Xn a‐Xn b‐RRRQRRKKR、DQSRPVQPFLNLTTPR‐Xn a‐Xn b‐RRRQRRKKR、DQSRPVQPFLNLTTP‐Xn a‐Xn b‐RRRQRRKKR、DQSRPVQPFLNLTT‐Xn a‐Xn b‐RRRQRRKKR、または、QSRPVQPFLNLTTPRKP‐Xn a‐Xn b‐RRRQRRKKR、SRPVQPFLNLTTPRKP‐Xn a‐Xn b‐RRRQRRKKR、SRPVQPFLNLTTPRK‐Xn a‐Xn b‐RRRQRRKKR、RPVQPFLNLTTPRKP‐Xn a‐Xn b‐RRRQRRKKR、RPVQPFLNLTTPRK‐Xn a‐Xn b‐RRRQRRKKR、または、PVQPFLNLTTP‐Xn a‐Xn b‐RRRQRRKKR、QSRPVQPFLNLTTPRKPR‐Xn a‐Xn b‐RRRQRRKK、SRPVQPFLNLTTPRKPR‐Xn a‐Xn b‐RRRQRRKKRG、RPVQPFLNLTTPRKPR‐Xn a‐Xn b‐RRRQRRKK、PVQPFLNLTTPRKPR‐Xn a‐Xn b‐RRRQRRKK、または、VQPFLNLTTPRKPR‐Xn a‐Xn b‐RRRQRRKK、あるいは、それぞれ、DQSRPVQPFLNLTTPRKP‐Xn a‐Xn b‐RRRQRRKK、DQSRPVQPFLNLTTPRK‐Xn a‐Xn b‐RRRQRRKK、DQSRPVQPFLNLTTPR‐Xn a‐Xn b‐RRRQRRKK、DQSRPVQPFLNLTTP‐Xn a‐Xn b‐RRRQRRKK、DQSRPVQPFLNLTT‐Xn a‐Xn b‐RRRQRRKK、または、QSRPVQPFLNLTTPRKP‐Xn a‐Xn b‐RRRQRRKK、SRPVQPFLNLTTPRKP‐Xn a‐Xn b‐RRRQRRKK、SRPVQPFLNLTTPRK‐Xn a‐Xn b‐RRRQRRKK、RPVQPFLNLTTPRKP‐Xn a‐Xn b‐RRRQRRKK、RPVQPFLNLTTPRK‐Xn a‐Xn b‐RRRQRRKK、または、PVQPFLNLTTP‐Xn a‐Xn b‐RRRQRRKK、QSRPVQPFLNLTTPRKPR‐Xn a‐Xn b‐RRQRRKKR、SRPVQPFLNLTTPRKPR‐Xn a‐Xn b‐RRQRRKKR、RPVQPFLNLTTPRKPR‐Xn a‐Xn b‐RRQRRKKR、PVQPFLNLTTPRKPR‐Xn a‐Xn b‐RRQRRKKR、または、VQPFLNLTTPRKPR‐Xn a‐Xn b‐RRQRRKKR、あるいは、それぞれ、DQSRPVQPFLNLTTPRKP‐Xn a‐Xn b‐RRQRRKKR、DQSRPVQPFLNLTTPRK‐Xn a‐Xn b‐RRQRRKKR、DQSRPVQPFLNLTTPR‐Xn a‐Xn b‐RRQRRKKR、DQSRPVQPFLNLTTP‐Xn a‐Xn b‐RRQRRKKR、DQSRPVQPFLNLTT‐Xn a‐Xn b‐RRQRRKKR、または、QSRPVQPFLNLTTPRKP‐Xn a‐Xn b‐RRQRRKKR、SRPVQPFLNLTTPRKP‐Xn a‐Xn b‐RRQRRKKRG、SRPVQPFLNLTTPRK‐Xn a‐Xn b‐RRQRRKKRG、RPVQPFLNLTTPRKP‐Xn a‐Xn b‐RRQRRKKRG、RPVQPFLNLTTPRK‐Xn a‐Xn b‐RRQRRKKRG、または、PVQPFLNLTTP‐Xn a‐Xn b‐RRQRRKKRG、QSRPVQPFLNLTTPRKPR‐Xn a‐Xn b‐RRQRRKKRG、SRPVQPFLNLTTPRKPR‐Xn a‐Xn b‐RRQRRKKRG、RPVQPFLNLTTPRKPR‐Xn a‐Xn b‐RRQRRKKRG、PVQPFLNLTTPRKPR‐Xn a‐Xn b‐RRQRRKKRG、または、VQPFLNLTTPRKPR‐Xn a‐Xn b‐RRQRRKKRG、あるいは、それぞれ、DQSRPVQPFLNLTTPRKP‐Xn a‐Xn b‐RRQRRKKRG、DQSRPVQPFLNLTTPRK‐Xn a‐Xn b‐RRQRRKKRG、DQSRPVQPFLNLTTPR‐Xn a‐Xn b‐RRQRRKKRG、DQSRPVQPFLNLTTP‐Xn a‐Xn b‐RRQRRKKRG、DQSRPVQPFLNLTT‐Xn a‐Xn b‐RRQRRKKRG、または、QSRPVQPFLNLTTPRKP‐Xn a‐Xn b‐RRQRRKKRG、SRPVQPFLNLTTPRKP‐Xn a‐Xn b‐RRQRRKKRG、SRPVQPFLNLTTPRK‐Xn a‐Xn b‐RRQRRKKRG、RPVQPFLNLTTPRKP‐Xn a‐Xn b‐RRQRRKKRG、RPVQPFLNLTTPRK‐Xn a‐Xn b‐RRQRRKKRG、または、PVQPFLNLTTP‐Xn a‐Xn b‐RRQRRKKRG、QSRPVQPFLNLTTPRKPR‐Xn a‐Xn b‐RQRRKKRG、SRPVQPFLNLTTPRKPR‐Xn a‐Xn b‐RQRRKKRG、RPVQPFLNLTTPRKPR‐Xn a‐Xn b‐RQRRKKRG、PVQPFLNLTTPRKPR‐Xn a‐Xn b‐RQRRKKRG、または、VQPFLNLTTPRKPR‐Xn a‐Xn b‐RQRRKKRG、あるいは、DQSRPVQPFLNLTTPRKP‐Xn a‐Xn b‐RQRRKKRG、DQSRPVQPFLNLTTPRK‐Xn a‐Xn b‐RQRRKKRG、DQSRPVQPFLNLTTPR‐Xn a‐Xn b‐RQRRKKRG、DQSRPVQPFLNLTTP‐Xn a‐Xn b‐RQRRKKRG、DQSRPVQPFLNLTT‐Xn a‐Xn b‐RQRRKKRG、または、QSRPVQPFLNLTTPRKP‐Xn a‐Xn b‐RQRRKKRG、SRPVQPFLNLTTPRKP‐Xn a‐Xn b‐RQRRKKRG、SRPVQPFLNLTTPRK‐Xn a‐Xn b‐RQRRKKRG、RPVQPFLNLTTPRKP‐Xn a‐Xn b‐RQRRKKRG、RPVQPFLNLTTPRK‐Xn a‐Xn b‐RQRRKKRG、または、PVQPFLNLTTP‐Xn a‐Xn b‐RQRRKKRG。
なお、ペプチドが短くなれば、該ペプチドの(非特異的な)細胞毒性は低くなる。しかし、ペプチドは、生物機能(すなわち、該ペプチドの細胞膜透過性(第1ドメイン)、および、該ペプチドのJNK阻害機能(第2ドメイン))を保っている必要がある。
(i)本発明のJNK阻害剤配列および/または本発明キメラペプチド、ならびに/あるいは、それらの変異体、断片または誘導体の何れかを1以上、ならびに/あるいは、
(ii)本発明のJNK阻害剤配列および/または本発明のキメラペプチド、ならびに/あるいは、それらの変異体、断片または誘導体をコードする核酸、ならびに/あるいは、
(iii)本発明のJNK阻害剤配列および/または本発明のキメラペプチド、ならびに/あるいは、それらの変異体、断片または誘導体の何れかを1以上含んでいる細胞、ならびに/あるいは、
(iv)本発明のJNK阻害剤配列および/または本発明のキメラペプチド、ならびに/あるいは、それらの変異体、断片または誘導体をコードするベクターおよび/または核酸によりトランスフェクトされた細胞、
を含んでいる。
(i)JNKが活性化していることが頻繁に実証されている、様々な臓器系(肺、乳房、リンパ組織、胃腸および尿生殖路など)の悪性腫瘍、ならびに、
(ii)悪性腫瘍(大部分の大腸癌、腎細胞癌、前立腺癌、肺の非小細胞癌、小腸の癌および食道癌など)を含んでいる腺癌、
を予防および/または治療することに、本発明薬理学的組成物を用いてもよい。また、白血病、発癌性形質転換に関係する疾患または病態生理、ならびにJNKの活性化を明らかに必要とするBcr‐Ablにより発癌性形質転換された癌、も含まれる。
図1A‐Cは、示された転写因子における保存されたJBDドメイン領域のアライメントを示す図である。JNK阻害剤配列を、これらの配列のアライメントを精査することによって同定した。このアライメントの結果を、図1A〜1Cに例として示す。図1Aは、IB1、IB2、c‐JunおよびATF2のJDB同士の間において、最も高い相同性がある領域を示している。パネルBは、L‐IB1およびL‐IB1のJBSのアミノ酸配列を、比較するために示している。完全に保存されている残基を、アスタリスクで示す。また、GFP‐JBD23Mutベクターにおいてアラニンに変化した残基を、白丸で示す。図1Cは、JNK阻害剤配列および輸送配列を含んでいるキメラタンパク質のアミノ酸配列を示している。示された例では、輸送配列は、ヒト免疫不全ウィルス(HIV)のTATポリペプチドに由来し、JNK阻害剤配列は、IB1ポリペプチドに由来する。ヒト、マウスおよびラットの配列が、パネルBおよびCにおいて示されている。
<実施例1:JNK阻害剤の配列の同定>
JNKと効率的に相互作用するために重要なアミノ酸配列を、公知のJBD同士の配列アライメントにより、同定した。IB1(配列番号13)、IB2(配列番号14)、c‐Jun(配列番号15)、および、ATF2(配列番号16)というJBD同士の配列を比較することにより、弱く保存された8アミノ酸配列(図1A)が明らかになった。IB1およびIB2というJBDのJNKに対する結合力は、c‐JunまたはATF2のJNKに対する結合力よりも、100倍強いので(「Dickens ら Science 277 :693(1977)」)、IB1とIB2との間に保存された残基は、最大結合を付与することにとって重要であるに違いない、という結論が導かれた。IB1およびIB2というJBD同士を比較することで、2つの配列の間において高く保存されている7アミノ酸および3アミノ酸の2つのブロックが明らかになった。
配列番号9に記載の本発明のJNK阻害剤融合タンパク質を、2つのプロリン残基から成るリンカーを介して、配列番号1に記載のC‐末端と、配列番号5に記載のHIV‐TAT4g 57(「Vives ら, J Biol. Chem. 272: 16010 (1997)」)に由来するN‐末端10アミノ酸長担体ペプチドとを共有結合させることにより合成した。前記リンカーを、柔軟性を最大にするためおよび二次的構造の好ましくない変化を防ぐために使用した。また、基本コンストラクトは、L‐IB1(配列番号1)およびL‐TAT(配列番号5)をそれぞれ調製および設計された。
JNKの生物活性に対するIB1の19aa長JBD配列の効果を、研究した。19aa配列は、N‐末端において緑蛍光性タンパク質と結合させた(GFP JBD19コンストラクト)。そして、IL1によって誘導された膵臓β細胞アポトーシスに対する前記コンストラクトの効果を、評価した。このアポトーシスの形態は、JBD1‐280のトランスフェクションすることにより妨害されることを予め示したが、ERK1/2またはp38に特異的な阻害剤により、防がれなかった(上記のAmmendrup らを参照)。
細胞に浸入するための、(i)TATペプチドおよび(ii)TAT-IB1ペプチド(TAT‐IBペプチド)のL‐およびD‐鏡像異性体の能力を評価した。L‐TAT、D‐TAT、本発明のL‐TAT‐IB1、および本発明のD‐TAT‐IB1ペプチド(それぞれ配列番号5、6、9、および12)を、蛍光色素に接合されたグリシン残基をN‐末端に付加することにより、標識した。標識ペプチド(1μM)を、実施例3に記載したように培養されているβTC‐3細胞の培養物に添加した。所定時間において細胞をPBSで洗浄し、次に、蛍光顕微鏡の下に検査する前に、氷冷のメタノール‐アセトン(1:1)に5分間固定した。フルオレセインで標識したBSA(1μM、12モル/モルBSA)を、対照として使用した。上記の全てのフルオレセインで標識されたペプチドは、培地に添加されると、効率的に、且つ、迅速に細胞に浸入した(5分間よりも短い)という結果が得られた。反対に言えば、フルオレセインで標識されたウシ血清アルブミン(1μM BSA、12モルフルオレセイン/モルBSA)は、細胞に浸入しなかった。
標的転写因子のJNKsに媒介されるリン酸化に対するペプチドの効果を、インビトロにおいて研究した。活性化していない組み換えJNK1、JNK2、およびJNK3を、転写・翻訳ウサギ赤血球溶解液キット(Promega)を用いて、生産した。c‐Jun、ATF2およびElk1(単独か、またはグルタチオン‐S‐トランスフェラーゼ(GST)と融合したもののどちらか)を基質として用いて固相キナーゼアッセイに使用した。本発明のL‐TATまたはL‐TAT‐IB1ペプチド(0‐25μM)を、反応緩衝液(20 mM Tris‐acetate、1mM EGTA、10mM p‐ニトロフェニル‐ホスフェート(pNPP)、5mMピロリン酸ナトリウム、10mM p‐グリセロホスフェト、1mMジチオスレイトール)において、組み換えJNK1キナーゼ、JNK2キナーゼ、または、JNK3キナーゼと20分間混合して、用量反応研究を行った。それから、10mM MgCl2、ならびに、5pCi 33P‐γ‐dATP、およびGST‐Jun(aa 1‐89)、GST‐AFT2(aa 1‐96)、またはGST‐ELK1(aa 307‐428)のどれかを1μg添加することにより、キナーゼ反応を開始させた。GST‐融合タンパク質を、ストラタジーン社(La JoIIa, CA)から購入した。
ストレス刺激により活性化したJNKsに対する、L‐TATまたは本発明のL‐TAT‐IB1ペプチドの効果を、JNKsをプルダウンするためのGST‐Junを使用して、紫外光線を照射したHeLa細胞、または、IL‐1βを用いて処理されたPTC細胞から評価した。PTC細胞を、上記のように培養した。HeLa細胞を、10%ウシ胎仔血清、100μg/mLスレプトマイシン、100ユニット/mlペニシリン、および、2mMグルタミンを追加したDMEM培地に、培養した。細胞抽出物調製のために使用される1時間前に、HeLa細胞を紫外線(20J/m2)により活性化し、PTC細胞は上記のようにIL‐1βと一緒に活性化した。細胞抽出物を、溶解緩衝液(20mM Tris‐acetate、1mM EGTA、1% TritonX‐100、10mM p‐ニトロフェニル‐ホスフェート、5mMピロリン酸ナトリウム、10mM P‐グリセロホスフェート、1mMジチオスレイトール)中で細胞培養をスクレーピングすることにより、対照、紫外光線を照射したHeLa細胞、および、IL‐1βを用いて処理されたβTC‐3細胞から調製した。残骸物(debris)を、SS‐34ベックマンローターにおいて、15,000rpmで5分間遠心分離することにより除去した。1‐100μg抽出物を、1μgのGST‐jun(アミノ酸1‐89)および10μLのグルタチオン‐アガロースビーズ(Sigma)と一緒に、室温で1時間インキュベーションした。スクレーピング緩衝液と一緒に4回洗浄した後、前記ビーズを、L‐TATまたは本発明のL‐TAT‐IB1ペプチド(25μM)が添加されている同じ緩衝液に20分間再懸濁した。それから、10mMMgCl2および5 pCi33P‐γ‐dATPを添加してキナーゼ反応を開始させて、30℃で30分間インキュベーションした。
本発明の細胞透過性ペプチドがインビボにおいてJNKのシグナル伝達を防ぐことができるかどうかを決定するために、非相同のGAL4システムを使用した。上記のように培養されたHeLa細胞を、GAL4 DNA結合ドメインに連結したc‐Junの活性化ドメイン(アミノ酸1‐89)を含んでいるGAL‐Jun発現コンストラクト(Stratagene)と、5xGAL‐LUCのレポーターベクターと一緒に同時トランスフェクションした。直接の上流キナーゼであるMKK4およびMKK7(「Whitmarshら., Science 285: 1573 (1999)」を参照)を発現するベクターの同時トランスフェクションにより、JNKを活性化させた。つまり、製造者の説明書によりDOTAP(Boehringer Mannheim)を使用して、3×105細胞に、3.5cmのディッシュにプラスミドをトランスフェクションした。GAL‐Junに関する実験のために、上記プラスミド(20ng)、レポータープラスミドであるpFR‐Luc(Stratagene)(1μg)、および、MKK4かMKK7を発現するプラスミド(0.5μg)を一緒にトランスフェクションした。トランスフェクションから3時間後、培養液を変えて、TATおよびTAT‐IB1ペプチド(1μM)を添加した。16時間後に、タンパク質の含有量に対して正規化を行った後、ルシフェラーゼ活性を、「2重報告システム(Dual Reporter System)」(Promega)を使用して測定した。TAT‐IB1ペプチドを添加することにより、MKK4およびMKK7に媒介されるJNKの活性化によるc‐Junの活性化が防止された。HeLa細胞は、JNK1およびJNK2のアイソフォームを発現しているが、JNK3のアイソフォームは発現していないので、JNK3を細胞にトランスフェクションした。また、TAT‐IBペプチドは、JNK2に媒介されるc‐Junの活性化を抑制した。
IL‐1により誘発されたβ細胞のアポトーシスの促進に対する本発明のL‐TAT‐IBペプチドの効果を研究した。βTC‐3細胞培養物を、本発明の1μMのL‐TAT‐IB1ペプチドと一緒に30分間インキュベーションし、その後10ng/mL IL‐1を添加した。2回目のペプチド(1μM)の添加は、24時間後に行った。IL‐1βと一緒に2日間インキュベーションした後に、染色法のプロピジウムヨウ化物(赤く染色された細胞は死細胞である)およびHoechst 33342(青く染色された細胞は無傷の原形質膜である)を用いて、アポトーシスを起こした細胞を計測した。本発明のTAT‐IBペプチドを添加することにより、2日間IL‐1βの存在下において培養されたβTC‐3細胞のIL‐1に誘導されるアポトーシスが抑制された。
本発明のペプチドは、タンパク質の自然分解を防ぐために、反対に合成されたall‐D‐アミノ酸ペプチドであってもよい(すなわち、all‐D‐レトロ‐インベルソペプチド)。本発明のall‐D‐レトロインベルソペプチドは、天然ペプチドに類似の機能特性を有するペプチドを提供する。なお、アミノ酸の構成要素の側基は、天然ペプチドアライメントに相当するであろうが、プロテアーゼ耐性のバックボーンを保有しているであろう。
実施例5に記載したように、天然プロテアーゼによる分解から本発明のD‐TAT‐IBペプチドが保護されるために、天然L‐アミノ酸類似体と比較したときに、ペプチドヘテロ接合を含んでいる本発明のD‐TAT‐IBレトロ‐インベルソの生物活性が長続きすることを、予想できた。
JNKは電離放射線によっても活性化する。本発明のTAT‐IBペプチドが、放射線に誘導されるJNK損傷に対する保護を提供するかどうかを決定するために、D‐TAT、本発明のL‐TAT‐IB1ペプチドまたは本発明のD‐TAT‐IB1ペプチドが存在する場合と、存在しない場合とについて、「WiDr」細胞に放射線を浴びせた(30Gy)。なお、上記ペプチドが存在する場合は、放射線を浴びせる30分前に、上記ペプチドを1μM添加した。対照細胞(CTRL)は、放射線を浴びていかった。細胞を、上記のように、P1およびHoechst3342の染色を用いて48時間後に解析した。標準誤差(SEM)を示す(n=3)。本発明のL‐TAT‐IB1ペプチドおよびD‐TATIBペプチドは、両方とも、このヒトの結腸癌細胞株における放射線に誘導されるアポトーシスを防ぐことができる。
本発明のTAT‐IBペプチドの放射線防護の効果を決定するために、フィリップRT 250 R‐rayを用いて、0.74Gy/min(17mA、0.5mm 銅フィルタ)の線量率で放射線を、C57B1/6マウス(2〜3月齢)放射線に照射した。照射する30分前に、TAT、本発明のL‐TAT‐IB1ペプチド、または本発明のD‐TAT‐IB1ペプチドのどれかを、前記マウスの腹腔内に注射した(1mM溶液の301)。つまり、次のようにマウスに照射した。(i)マウスの頭を小さなプラスチック箱の外に横たわらす状態で、マウスを該箱に配置した。(ii)前記マウスを、照射器の下にマウスを仰向けにして配置し、つぎに、(iii)マウスの頭を正しい位置に維持できるように、マウスの首を小さなプラスチック性のトンネルに固定した。(iv)マウスの体を鉛で保護した。
ゲルリターデイションアッセイを、AP‐1 二重標識プローブ(5'- CGC TTG ATG AGT CAG CCG GAA-3'(配列番号27))を用いて行った。上記のように5ng/mlのTNF‐αにより1時間処理されたまたは処理されていないHeLa細胞核を抽出する。TATおよび本発明のL‐TAT‐IB1ペプチドを、TNF‐αにより処理する30分前に添加した。特異的なAP‐1 DNA複合体(非標識の特異的な競合物および標識された非特異的な競合物を用いた競合実験により実証されるようなAP‐1 DNA複合体)を有するゲルの部分だけを示す。
局所性脳虚血は、12日齢のラットに引き起こされた。幼若ラットを、2%イソフルレンを用いて誘導チェンバーにおいて麻酔した。そして、手術の間、麻酔を、2%イソフルレン未満のマスクを用いて維持した。MCAOを、中大脳動脈(MCA)の主枝を電気凝固することにより引き起こした。ラットを右側を下にして配置し、耳と目との間において、皮膚を斜めに切開した。側頭筋を切除した後、頭蓋骨を、前頭縫合線から頬骨弓より下の部位まで除去した。左のMCAが嗅脳溝上に現れたあとに、該MCAを露出させた。そして、前頭枝と前頂枝とに二分岐する前のMCAにおいて、下大脳静脈の段階で、MCAを恒久的に電気凝固した。それから、頭蓋の皮膚切開部分を閉じた。それから、幼若ラットが目覚めるまで、37℃を維持した保温器に配置し、ラットの母親に委ねた。
『成体マウスにおける一過性虚血』。雄マウスICR‐CD1(6週齢;18‐37g;ハーラン(Harlan))を用いて、(i)内頚動脈へ、総頚動脈から微細繊維を導入し、(ii)動脈輪へ、該微細繊維を進行させ、それによって、(iii)中大脳動脈を塞ぐことにより、虚血を誘発した。再かん流から10分後まで、頭蓋骨を固定するプローブを用いてレーザードップラー流量測定法により、虚血の全域にわたって局所脳血流を測定した。
対照 n=5 72 17
XG102 0.3 n=5 16 4
XG102 1 n=1 16
XG102 3 n=5 15 5
100μM NMDAに継続的に照射される前に、示された濃度のペプチドまたはMK‐801を用いて30分間予め処置された姉妹培養物における、一般式で表されたD‐TAT‐IB/D‐JNKl1ペプチド(配列番号12)の神経防護の効果を評価した。対照と比べてLDHの放出が顕著に抑制されていることから分かるように、NMDA処理から12時間後、一般式で表された5μMのD‐TAT‐IB/D‐JNKl1を用いて予め処理された培養物において、NMDAの暴露に起因する変性変化が完全に阻害された(図5)。形態学的な外見、数および分布は対照と変わらなかった。
HepG2細胞を、実験前日に、3,000細胞/ウェルで接種した。それから、JNKを活性させるために、インターロイキン‐1β[IL‐1β(ν)]、または腫瘍壊死因子α[TNFα(●)]のどれかの濃度を増やしながら30分間添加した(a)。細胞を、20mM Hepes、0.5%Tween pH7.4の溶液に溶かし、そして、アルファスクリーン(AlphaScreen)JNK用に処理した。(b)JNK活性に関するZ'を、10ng/ml IL‐1βにより誘導した、および384ウェル/プレート(n=96)において測定した。(c)キメラJNK阻害剤[スタウロスポリン(○)およびSP600125(●)]を用いた内在性のIL‐1βに誘導されるJNK活性の抑制を示す。(d)IL‐1α依存性のJNK活性に対する、(i)配列番号9に記載のペプチド阻害剤L‐TAT‐IB1(図6ではL‐JNKi(ν)と省略する)、(ii)配列番号11に記載のペプチド阻害剤D‐TAT‐IB1(図6ではD‐JNKi(◆)と省略する)、および(iii)JBD(●)(TAT配列を有していないL‐JNK1に相当する)の効果を示す。すべてのパネルは、3つの独立な実験を表す(n=3)。
理論:アルファスクリーン(AlphaScreen)(登録商標)は、マイクロプレートフォーマットにおいて、生体分子相互作用を研究するために用いられる、非放射活性ビーズに基づく技術である。ALPHAの頭文字は、増幅ルミネッセンス近接ホモジニアスアッセイ法(Amplified Luminescence Proximity Homogenous Assay)を意味している。それは、ごく近くに、「ドナー」および「アクセプタ」ビーズをもたらす生物学的な相互作用に関する。それから、化学反応のカスケードが作用して、増幅したシグナルが生産される。680nmにおけるレーザー励起により、「ドナー」ビーズにおける光線感作物質(フタロシアニン)は、周囲の酸素を励起一重項状態に転換させる。4μsec半減期内に、一重項酸素分子は、溶液において、およそ200nmまで拡散することができる。アクセプタビーズがその近接の範囲内であれば、一重項酸素は、「アクセプタ」ビーズにおけるチオキソ誘導体と反応する。これにより、該「アクセプタ」ビーズに含まれたフルオロフォアをさらに活性させる370nmの化学発光が生じる。励起状態のフルオロフォアは、その後に520‐620nmの光を放出する。アクセプタビーズがない場合、一重項酸素は基底状態に下降し、シグナルは発生されない。
モルモットの3グループ(各グループには6匹の動物が含まれる)は、100μMの濃度で、蝸牛窓の膜上に沈着された、2μlの2.6%の緩衝化したヒアルロン酸(Hylumed, Genzyme Corp.)ゲル中に含まれるD‐TAT‐IB1を、騒音(6kHzにおける120dB、30分間)による外傷を受ける30分前、30分後、または4時間の何れかに受け取った。対照として未処置の耳を設けた。騒音によって外傷を受けてから20分間後(一時的な閾値の変化、TTS)および15日後(永久的な閾値の変化、PTS)の聴覚脳幹反応測定により、聴力の閾値の変化を評価した。前記未処置の耳と比較して、D‐TAT‐IB1の投与をすることで、たとえ、過剰な騒音を晒した後に適用したとしても、永久的な聴力損失が防がれた。騒音によって外傷を受けた後に、D‐TAT‐IB1を早く投与すればするほど、防護効果が高かった。従って、騒音によって外傷を受けることについて、D‐TAT‐IB1は、非常に有効な耳を保護する化合物である。
本発明のJNK阻害剤配列では、前記JNK阻害剤配列のアミノ酸残基の範囲が、5‐150、より好ましくは10‐100、さらに好ましくは10‐75、および最も好ましくは15‐50である、ことが好ましい.
本発明のJNK阻害剤配列では、本発明は、前記JNK阻害剤配列がc‐Junアミノ端末キナーゼ(JNK)と結合する、ことが好ましい.
本発明のJNK阻害剤配列では、前記JNK阻害剤配列は、JNK阻害剤配列がJNKを発現する細胞に存在するときに、JNKが標的とする転写因子の少なくとも1つの活性化を阻害する、ことが好ましい.
本発明のJNK阻害剤配列では、前記JNKが標的とする転写因子が、c‐Jun、ATF2、およびElklから成る群より選ばれる、ことが好ましい.
本発明のJNK阻害剤配列では、前記JNK阻害剤配列は、ペプチドがJNKを発現する細胞に存在するときに、JNKの効果を変える、ことが好ましい.
また、本発明は、共有結合により連結した少なくとも1つの第1ドメインおよび少なくとも1つの第2ドメインを含んでいるキメラペプチドであって、前記第1ドメインは輸送配列を含んでおり、前記第2ドメインはJNK阻害剤配列を含んでいる、キメラペプチドに関する.
本発明のキメラペプチドでは、前記輸送配列が、ヒト免疫不全ウィルスのTATポリペプチドのアミノ酸配列を含んでいる、ことが好ましい.
本発明のキメラペプチドでは、前記輸送配列が、配列番号5、6、7、または8に記載のアミノ酸配列を含んでいる、ことが好ましい.
本発明のキメラペプチドでは、前記輸送配列が、ペプチドの細胞取り込みを増大させる、ことが好ましい.
本発明のキメラペプチドでは、ペプチドの核局在化を方向づける、ことが好ましい.
本発明のキメラペプチドでは、上記JNK阻害剤配列を含んでいる、ことが好ましい.
本発明のキメラペプチドでは、前記ペプチドが、配列番号9、10、11、または12の何れか1項に記載のアミノ酸配列、あるいはその断片または変異体を含んでいる、ことが好ましい.
また、本発明は、上記JNK阻害剤配列、または上記キメラペプチドをコードする単離された核酸に関する.
また、本発明は、上記核酸を含んでいるベクターに関する.
また、本発明は、上記ベクターを含んでいる細胞に関する.
また、本発明は、上記JNK阻害剤配列、または上記キメラペプチドと、免疫特異的に結合する抗体に関する.
また、本発明は、上記JNK阻害剤配列、または上記キメラペプチド、または上記核酸、および薬理学的に許容可能な担体を含んでいる薬理学的組成物に関する.
また、本発明は、被検体におけるJNKの活性化と関連する病態生理を治療するための薬理学的組成物を調製するための、上記JNK阻害剤配列または上記キメラペプチドの使用に関する.
本発明の使用では、前記病態生理は、肺、乳房、リンパ組織、胃腸および尿生殖路の悪性腫瘍、ならびに、大腸癌、腎細胞癌、前立腺癌、肺の非小細胞癌、小腸の癌および食道癌のような悪性腫瘍を含んでいる腺癌、ならびに、白血病、発癌性形質転換に関係する疾患または病態生理、およびBcr‐Ablにより発癌性形質転換された癌、乾癬、増殖性天疱瘡、ベーチェット症候群、急性呼吸窮迫候群(ARDS)、虚血性心疾患、透析後症候群、関節リウマチ、後天性免疫不全症候群、血管炎、敗血症ショックから選ばれる、悪性ではない、または免疫に関係している細胞増殖性の病気、再狭窄、聴力損失、耳の傷害、虚血、脳梗塞から選ばれる、細胞におけるJNKの活性化に関連する病態生理、および/または、免疫細胞の成熟および分化に関連している疾患もしくは病態生理、再かん流傷害、低酸素症、アポトーシスが関連している病気、ストレス刺激に対する反応、ならびに、炎症性サイトカインを用いた治療に起因する副次的効果に関連している疾患もしくは病態生理、糖尿病もしくは細胞のせん断応力に関連する影響であって、(i)心肥大および心臓肥大、動脈硬化性病変を含む動脈性高血圧により誘導される病理状態、ならびに、血管の分岐部における動脈性高血圧により誘導される病理状態、(ii)放射線療に用いられる電離放射線、および紫外線(紫外線光)により誘導される病理状態、(iii)化学療法薬を含むDNAに損害を与える作用物質に由来するフリーラジカルにより誘導される病理状態、(iv)虚血/再かん流傷害により誘導される病理状態、(v)低酸素により誘導される病理状態、(vi)高体温および低体温により誘導される病理状態から選ばれる、影響、あるいは、炎症性疾患、自己炎症性疾患、免疫疾患、自己免疫疾患、変性疾患、ミオパチー、心筋ミオパチー、および拒絶反応を阻害するための病理状態、であることが好ましい.
本発明の使用では、薬理学的組成物が、腹腔内送達、経鼻送達、静脈内送達、経口送達、およびパッチ送達から成る群より選択される投与経路により、投与される、ことが好ましい.
また、本発明は、上記キメラペプチドを調製するための方法であって、(a)キメラペプチドの発現を提供する条件下において上記核酸を含んでいる細胞を培養する工程、および(b)発現したペプチドを回収する工程を含んでいる方法に関する.
また、本発明は、上記JNK阻害剤配列、および/または、(ii)上記キメラペプチド、および/または、(iii)上記核酸、および/または、(iv)上記ベクター、および/または、(v)上記細胞、および/または、(vi)上記抗体を含んでいるキットに関する。
Claims (23)
- 長さが150アミノ酸よりも短いJNK阻害剤配列であって、前記阻害剤配列は配列番号1、2、3、もしくは4に記載のアミノ酸配列の少なくとも1つ、またはその断片、誘導体、もしくは変異体を含んでいるか、あるいは、上記アミノ酸の少なくとも1つ、またはそれらの断片、誘導体、もしくは変異体から成るJNK阻害剤配列。
- 前記JNK阻害剤配列のアミノ酸残基の範囲が、5‐150、より好ましくは10‐100、さらに好ましくは10‐75、および最も好ましくは15‐50である、請求項1に記載のJNK阻害剤配列。
- 前記JNK阻害剤配列がc‐Junアミノ端末キナーゼ(JNK)と結合する、請求項1または2の何れか1項に記載のJNK阻害剤配列。
- 前記JNK阻害剤配列は、JNK阻害剤配列がJNKを発現する細胞に存在するときに、JNKが標的とする転写因子の少なくとも1つの活性化を阻害する、請求項1〜3の何れか1項に記載のJNK阻害剤配列。
- 前記JNKが標的とする転写因子が、c‐Jun、ATF2、およびElklから成る群より選ばれる、請求項1〜4の何れか1項に記載のJNK阻害剤配列。
- 前記JNK阻害剤配列は、ペプチドがJNKを発現する細胞に存在するときに、JNKの効果を変える、請求項1〜5の何れか1項に記載のJNK阻害剤配列。
- 共有結合により連結した少なくとも1つの第1ドメインおよび少なくとも1つの第2ドメインを含んでいるキメラペプチドであって、前記第1ドメインは輸送配列を含んでおり、前記第2ドメインはJNK阻害剤配列を含んでいる、キメラペプチド。
- 前記輸送配列が、ヒト免疫不全ウィルスのTATポリペプチドのアミノ酸配列を含んでいる、請求項7に記載のペプチド。
- 前記輸送配列が、配列番号5、6、7、または8に記載のアミノ酸配列を含んでいる、請求項7または8の何れか1項に記載のペプチド。
- 前記輸送配列が、ペプチドの細胞取り込みを増大させる、請求項7〜9の何れか1項に記載のペプチド。
- 前記輸送配列が、ペプチドの核局在化を方向づける、請求項7〜9の何れか1項に記載のペプチド。
- 前記JNK阻害剤配列が、請求項1〜6の何れか1項に記載のJNK阻害剤配列を含んでいる、請求項7〜11の何れか1項に記載のペプチド。
- 前記ペプチドが、配列番号9、10、11、または12の何れか1項に記載のアミノ酸配列、あるいはその断片または変異体を含んでいる、請求項7〜12の何れか1項に記載のペプチド。
- 請求項1〜6の何れか1項に記載のJNK阻害剤配列、または請求項7〜13の何れか1項に記載のキメラペプチドをコードする単離された核酸。
- 請求項14に記載の核酸を含んでいるベクター。
- 請求項15に記載のベクターを含んでいる細胞。
- 請求項1〜6の何れか1項に記載のJNK阻害剤配列、または請求項7〜13の何れか1項に記載のキメラペプチドと、免疫特異的に結合する抗体。
- 請求項1〜6の何れか1項に記載のJNK阻害剤配列、または請求項7〜13の何れか1項に記載のキメラペプチド、または請求項14に記載の核酸、および薬理学的に許容可能な担体を含んでいる薬理学的組成物。
- 被検体におけるJNKの活性化と関連する病態生理を治療するための薬理学的組成物を調製するための、請求項1〜6の何れか1項に記載のJNK阻害剤配列または請求項9〜13の何れか1項に記載のキメラペプチドの使用。
- 前記病態生理は、
肺、乳房、リンパ組織、胃腸および尿生殖路の悪性腫瘍、ならびに、
大腸癌、腎細胞癌、前立腺癌、肺の非小細胞癌、小腸の癌および食道癌のような悪性腫瘍を含んでいる腺癌、ならびに、
白血病、発癌性形質転換に関係する疾患または病態生理、およびBcr‐Ablにより発癌性形質転換された癌、
乾癬、増殖性天疱瘡、ベーチェット症候群、急性呼吸窮迫候群(ARDS)、虚血性心疾患、透析後症候群、関節リウマチ、後天性免疫不全症候群、血管炎、敗血症ショックから選ばれる、悪性ではない、または免疫に関係している細胞増殖性の病気、
再狭窄、聴力損失、耳の傷害、虚血、脳梗塞から選ばれる、細胞におけるJNKの活性化に関連する病態生理、および/または、
免疫細胞の成熟および分化に関連している疾患もしくは病態生理、再かん流傷害、低酸素症、アポトーシスが関連している病気、ストレス刺激に対する反応、ならびに、炎症性サイトカインを用いた治療に起因する副次的効果に関連している疾患もしくは病態生理、
糖尿病もしくは細胞のせん断応力に関連する影響であって、(i)心肥大および心臓肥大、動脈硬化性病変を含む動脈性高血圧により誘導される病理状態、ならびに、血管の分岐部における動脈性高血圧により誘導される病理状態、(ii)放射線療に用いられる電離放射線、および紫外線(紫外線光)により誘導される病理状態、(iii)化学療法薬を含むDNAに損害を与える作用物質に由来するフリーラジカルにより誘導される病理状態、(iv)虚血/再かん流傷害により誘導される病理状態、(v)低酸素により誘導される病理状態、(vi)高体温および低体温により誘導される病理状態から選ばれる、影響、あるいは、
炎症性疾患、自己炎症性疾患、免疫疾患、自己免疫疾患、変性疾患、ミオパチー、心筋ミオパチー、および拒絶反応を阻害するための病理状態、
である請求項19に記載の使用。 - 薬理学的組成物が、腹腔内送達、経鼻送達、静脈内送達、経口送達、およびパッチ送達から成る群より選択される投与経路により、投与される、請求項19または20の何れか1項に記載の使用。
- 請求項7〜13の何れか1項に記載のキメラペプチドを調製するための方法であって、(a)キメラペプチドの発現を提供する条件下において請求項14に記載の核酸を含んでいる細胞を培養する工程、および(b)発現したペプチドを回収する工程を含んでいる方法。
- (i)請求項1〜6の何れか1項に記載のJNK阻害剤配列、および/または、(ii)請求項7〜13の何れか1項に記載のキメラペプチド、および/または、(iii)請求項14に記載の核酸、および/または、(iv)請求項15に記載のベクター、および/または、(v)請求項16に記載の細胞、および/または、(vi)請求項17に記載の抗体を含んでいるキット。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2005/009782 WO2007031098A1 (en) | 2005-09-12 | 2005-09-12 | Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
EPPCT/EP2005/009782 | 2005-09-12 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008530405A Division JP5386169B2 (ja) | 2005-09-12 | 2006-09-12 | Jnkシグナル伝達経路の細胞透過性ペプチド阻害剤 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014216270A Division JP2015034171A (ja) | 2005-09-12 | 2014-10-23 | Jnkシグナル伝達経路の細胞透過性ペプチド阻害剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012095657A true JP2012095657A (ja) | 2012-05-24 |
JP5727393B2 JP5727393B2 (ja) | 2015-06-03 |
Family
ID=35686501
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008530405A Active JP5386169B2 (ja) | 2005-09-12 | 2006-09-12 | Jnkシグナル伝達経路の細胞透過性ペプチド阻害剤 |
JP2012000381A Active JP5727393B2 (ja) | 2005-09-12 | 2012-01-05 | Jnkシグナル伝達経路の細胞透過性ペプチド阻害剤 |
JP2014216270A Withdrawn JP2015034171A (ja) | 2005-09-12 | 2014-10-23 | Jnkシグナル伝達経路の細胞透過性ペプチド阻害剤 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008530405A Active JP5386169B2 (ja) | 2005-09-12 | 2006-09-12 | Jnkシグナル伝達経路の細胞透過性ペプチド阻害剤 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014216270A Withdrawn JP2015034171A (ja) | 2005-09-12 | 2014-10-23 | Jnkシグナル伝達経路の細胞透過性ペプチド阻害剤 |
Country Status (25)
Country | Link |
---|---|
US (5) | US8748395B2 (ja) |
EP (3) | EP2418217B1 (ja) |
JP (3) | JP5386169B2 (ja) |
KR (1) | KR101305533B1 (ja) |
CN (1) | CN101263157B (ja) |
AU (1) | AU2006291541B2 (ja) |
BR (1) | BRPI0616824B8 (ja) |
CA (1) | CA2621337C (ja) |
CY (2) | CY1112924T1 (ja) |
DK (2) | DK1928903T3 (ja) |
EA (1) | EA014330B1 (ja) |
ES (2) | ES2388076T3 (ja) |
HK (3) | HK1118841A1 (ja) |
HR (2) | HRP20120598T1 (ja) |
HU (1) | HUE029132T2 (ja) |
IL (2) | IL189133A (ja) |
ME (2) | ME02426B (ja) |
NO (1) | NO342272B1 (ja) |
PL (2) | PL1928903T3 (ja) |
PT (1) | PT1928903E (ja) |
RS (2) | RS54701B1 (ja) |
SI (2) | SI1928903T1 (ja) |
UA (1) | UA98101C2 (ja) |
WO (2) | WO2007031098A1 (ja) |
ZA (1) | ZA200800848B (ja) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040082509A1 (en) | 1999-10-12 | 2004-04-29 | Christophe Bonny | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
US8183339B1 (en) | 1999-10-12 | 2012-05-22 | Xigen S.A. | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
US8080517B2 (en) | 2005-09-12 | 2011-12-20 | Xigen Sa | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
WO2007031098A1 (en) | 2005-09-12 | 2007-03-22 | Xigen S.A. | Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
CA2663545A1 (en) | 2006-09-19 | 2008-03-27 | Phylogica Limited | Neuroprotective peptide inhibitors of ap-1 signaling and uses thereof |
US8822409B2 (en) | 2007-06-20 | 2014-09-02 | Phylogica Limited | Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ARDS) and clinical disorders associated with therewith |
US11969501B2 (en) | 2008-04-21 | 2024-04-30 | Dompé Farmaceutici S.P.A. | Auris formulations for treating otic diseases and conditions |
KR20210107137A (ko) | 2008-04-21 | 2021-08-31 | 오토노미, 인코포레이티드 | 귀 질환 및 병태를 치료하기 위한 귀 조제물 |
KR101534422B1 (ko) | 2008-05-14 | 2015-07-09 | 오토노미, 인코포레이티드 | 귀 질환 치료를 위한 제어 방출형 코르티코스테로이드 조성물 및 방법 |
US8648119B2 (en) | 2008-05-23 | 2014-02-11 | Otonomy, Inc. | Controlled release immunomodulator compositions and methods for the treatment of otic disorders |
WO2009143865A1 (en) * | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
WO2009143864A1 (en) * | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases |
US8846770B2 (en) | 2008-06-18 | 2014-09-30 | Otonomy, Inc. | Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders |
WO2010011466A2 (en) | 2008-06-27 | 2010-01-28 | Otonomy, Inc. | Controlled-release cns modulating compositions and methods for the treatment of otic disorders |
US8349353B2 (en) | 2008-06-27 | 2013-01-08 | Otonomy, Inc. | Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders |
GB2461961A (en) * | 2008-07-14 | 2010-01-27 | Otonomy Inc | Sterile anti-apoptotic agent for treatment of ear diseases |
US8318817B2 (en) | 2008-07-21 | 2012-11-27 | Otonomy, Inc. | Controlled release antimicrobial compositions and methods for the treatment of otic disorders |
US8784870B2 (en) | 2008-07-21 | 2014-07-22 | Otonomy, Inc. | Controlled release compositions for modulating free-radical induced damage and methods of use thereof |
CA2731769C (en) | 2008-07-21 | 2013-09-10 | Otonomy, Inc. | Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders |
US8496957B2 (en) | 2008-07-21 | 2013-07-30 | Otonomy, Inc | Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders |
US8399018B2 (en) | 2008-07-21 | 2013-03-19 | Otonomy, Inc. | Controlled release ion channel modulator compositions and methods for the treatment of otic disorders |
WO2010048095A2 (en) | 2008-10-22 | 2010-04-29 | House Ear Institute | Treatment and/or prevention of inner ear conditions by modulation of a metabotropic glutamate receptor |
WO2010072228A1 (en) | 2008-12-22 | 2010-07-01 | Xigen S.A. | Novel transporter constructs and transporter cargo conjugate molecules |
KR20120022721A (ko) | 2009-03-30 | 2012-03-12 | 산텐 세이야꾸 가부시키가이샤 | JNK(c-Jun 아미노 말단 키나제) 저해 펩티드를 이용한 망막 질환의 예방 또는 치료제, 망막 질환의 예방 또는 치료 방법, 및 이 펩티드의 용도 |
WO2010151638A1 (en) * | 2009-06-25 | 2010-12-29 | Medical College Of Georgia Research Institute, Inc. | Jnk inhibitors for use in treating spinal muscular atrophy |
WO2011160653A1 (en) * | 2010-06-21 | 2011-12-29 | Xigen S.A. | Novel jnk inhibitor molecules |
WO2012048721A1 (en) | 2010-10-14 | 2012-04-19 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases |
KR20140099526A (ko) * | 2011-11-30 | 2014-08-12 | 자이겐 인플라메이션 리미티드 | 안구 건조증의 치료를 위한 jnk 신호 전달 경로의 세포-투과성 펩타이드 억제자의 용도 |
WO2013091670A1 (en) | 2011-12-21 | 2013-06-27 | Xigen S.A. | Novel jnk inhibitor molecules for treatment of various diseases |
CA2903275A1 (en) * | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
WO2015197097A1 (en) | 2014-06-26 | 2015-12-30 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
WO2016055160A2 (en) | 2014-10-08 | 2016-04-14 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
WO2015197098A1 (en) | 2014-06-26 | 2015-12-30 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
WO2014206427A1 (en) | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
WO2014206426A1 (en) * | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
EP3038707A4 (en) | 2013-08-27 | 2017-03-01 | Otonomy, Inc. | Treatment of pediatric otic disorders |
US9926354B2 (en) | 2014-01-09 | 2018-03-27 | University Of South Florida | Amyloid precursor protein (APP) based Ã#-secretase inhibitor peptides, and methods of use |
US20150306178A1 (en) * | 2014-04-23 | 2015-10-29 | Auris Medical Ag | Methods and compositions for treating and preventing tinnitus |
EP3160989A2 (en) * | 2014-06-26 | 2017-05-03 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
WO2015200768A2 (en) * | 2014-06-26 | 2015-12-30 | Auris Medical Ag | Pharmacologic treatments of menière's disease |
WO2016100909A1 (en) | 2014-12-18 | 2016-06-23 | President And Fellows Of Harvard College | METHODS FOR GENERATING STEM CELL-DERIVED β CELLS AND USES THEREOF |
US10456475B2 (en) | 2015-02-03 | 2019-10-29 | Kennsaw State University Research and Service Foundation, Inc. | Cell penetrating protein adaptor molecules and their application in research and medicine |
US10435446B2 (en) | 2015-06-03 | 2019-10-08 | Kennesaw State University Research and Service Foundation Inc. | Cell penetrating protein adaptor molecules and their application in research and medicine |
US10654894B2 (en) | 2016-02-03 | 2020-05-19 | Keenesaw State University Research And Service Foundation, Inc. | Methods for delivering cargo into a cell by using signal molecules as cell penetration agents |
WO2018029336A1 (en) | 2016-08-12 | 2018-02-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for determining whether a subject was administered with an activator of the ppar beta/delta pathway. |
EP3512513A4 (en) | 2016-09-16 | 2020-04-15 | Otonomy, Inc. | GEL FORMULA FOR THE EAR FOR TREATING OTITIS EXTERNA |
JP7291399B2 (ja) * | 2017-05-03 | 2023-06-15 | ティン セラピューティクス エルエルシー | 難聴の予防および治療のための組成物および方法 |
IT202000011176A1 (it) | 2020-05-15 | 2021-11-15 | Univ Degli Studi Milano | Peptidi inibitori di jnk3 |
US11857551B1 (en) | 2020-07-10 | 2024-01-02 | Ting Therapeutics Llc | Methods for the prevention and treatment of hearing loss |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003511071A (ja) * | 1999-10-12 | 2003-03-25 | ユニバーシティ オブ ローザンヌ | Jnkシグナル導入経路の細胞透過性ペプチドインヒビター |
WO2003103698A1 (en) * | 2002-06-07 | 2003-12-18 | University Of Lausanne | Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
Family Cites Families (130)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1195304B (it) | 1981-12-22 | 1988-10-12 | Anic Spa | Metodo per la preparazione di gem-diammino derivati n-monoacilati |
US4631211A (en) | 1985-03-25 | 1986-12-23 | Scripps Clinic & Research Foundation | Means for sequential solid phase organic synthesis and methods using the same |
US4698327A (en) | 1985-04-25 | 1987-10-06 | Eli Lilly And Company | Novel glycopeptide derivatives |
US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
IT1190389B (it) | 1985-09-19 | 1988-02-16 | Eniricerche Spa | Esapeptidi ad attivita' ipotensiva |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5169933A (en) | 1988-08-15 | 1992-12-08 | Neorx Corporation | Covalently-linked complexes and methods for enhanced cytotoxicity and imaging |
IT1227907B (it) | 1988-12-23 | 1991-05-14 | Eniricerche S P A Milano Sclav | Procedimento per la sintesi di peptidi retro-inversi e nuovi intermediin tale procedimento |
JP2752788B2 (ja) | 1989-01-23 | 1998-05-18 | カイロン コーポレイション | 感染および過剰増殖障害の為の組換え療法 |
GB8919607D0 (en) | 1989-08-30 | 1989-10-11 | Wellcome Found | Novel entities for cancer therapy |
US5652122A (en) | 1989-12-21 | 1997-07-29 | Frankel; Alan | Nucleic acids encoding and methods of making tat-derived transport polypeptides |
US5804604A (en) | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
US6316003B1 (en) | 1989-12-21 | 2001-11-13 | Whitehead Institute For Biomedical Research | Tat-derived transport polypeptides |
US5840313A (en) | 1990-09-27 | 1998-11-24 | Syntello Vaccine Development Kb | Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus |
AU1753892A (en) | 1991-04-10 | 1992-11-17 | General Hospital Corporation, The | Mammalian gap-43 compositions and methods of use |
US5994108A (en) | 1991-11-05 | 1999-11-30 | Board Of Regents, The University Of Texas System | Mutant TAR virus and transdominant tat mutants as pharmacological agents |
US5350835A (en) | 1991-11-05 | 1994-09-27 | Board Of Regents, University Of Texas | Cellular nucleic acid binding protein and uses thereof in regulating gene expression and in the treatment of aids |
CA2131620A1 (en) | 1992-03-20 | 1993-09-30 | Louis C. Smith | A dna transporter system and method of use |
ATE260679T1 (de) | 1992-04-03 | 2004-03-15 | Univ California | Selbstorganisierendes system zur verabreichung von polynukleotiden enthaltend ein amphiphatisches peptid |
WO1994004562A1 (en) | 1992-08-13 | 1994-03-03 | The General Hospital Corporation | Mammalian gap-43 compositions and methods of use |
NZ255831A (en) | 1992-08-21 | 1997-04-24 | Biogen Inc | Fusion proteins comprising biologically active cargo moiety and transport peptides from the hiv tat protein, their preparation and use |
BR9306984A (pt) | 1992-08-27 | 1999-01-12 | Deakin Res Ltd | Análogo de antígeno de peptídeo de um antígeno de peptídeo nativo vacina anticorpo processo para vacinar um hospedeiro necessitando deste tratamento estojo diagnóstico processos para preparar um análogo de um antiígeno de um antígeno de peptídeo nativo para preparar uma vacina para analisar uma amostra para um antígeno de peptídeo nativo e para analisar uma amostra para um anticorpo |
US5545551A (en) | 1992-08-28 | 1996-08-13 | Mt. Sinai School Of Medicine Of The City University Of New York | Cloning and expression of pur protein |
JP3789930B2 (ja) | 1992-10-09 | 2006-06-28 | アドバンスド ティシュー サイエンシズ,インコーポレーテッド | 肝予備細胞 |
WO1994023751A1 (de) | 1993-04-14 | 1994-10-27 | Boehringer Mannheim Gmbh | Nukleinsäure-transferpeptide und deren verwendung zur einschleusung von nukleinsäuren in eukaryontische zellen |
AU8116494A (en) | 1993-11-12 | 1995-06-13 | Kenichi Matsubara | Gene signature |
US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
US5807746A (en) | 1994-06-13 | 1998-09-15 | Vanderbilt University | Method for importing biologically active molecules into cells |
JPH10508205A (ja) | 1995-04-25 | 1998-08-18 | バクスター インターナショナル インコーポレイテッド | 肝細胞および膵臓ランゲルハンス島細胞を単離するためのコラーゲナーゼおよびキモパパインを含有する組成物 |
ATE365808T1 (de) | 1995-07-28 | 2007-07-15 | Marie Curie Cancer Care | Transportproteine und deren verwendungen |
WO1997010836A1 (en) | 1995-09-21 | 1997-03-27 | Innapharma, Inc. | Peptides and peptidomimetics inhibiting the oncogenic action of p21 ras |
IE80466B1 (en) | 1995-11-10 | 1998-07-29 | Elan Corp Plc | Peptides which enhance transport across tissues and methods of identifying and using the same |
US5877282A (en) | 1996-09-20 | 1999-03-02 | Bristol-Myers Squibb Company | Peptide inhibitors of nuclear protein translocation having nuclear localization sequences and methods of use thereof |
US6187817B1 (en) | 1996-10-03 | 2001-02-13 | Southern Illinois University School Of Medicine | Therapeutic use of d-methionine to reduce the toxicity of platinum-containing anti-tumor compounds |
US6361938B1 (en) | 1996-11-08 | 2002-03-26 | Elan Corporation, Plc | Peptides which enhance transport across tissues and methods of identifying and using the same |
WO1998023781A1 (en) | 1996-11-26 | 1998-06-04 | Johns Hopkins University | Ligand detection system and methods of use thereof |
US5989814A (en) | 1997-04-01 | 1999-11-23 | Reagents Of The University Of California | Screening methods in eucaryotic cells |
US5880261A (en) | 1997-04-03 | 1999-03-09 | Waeber; Gerard | Transcription factor Islet-Brain 1 (IB1) |
AU6972798A (en) | 1997-04-18 | 1998-11-13 | University Of Medicine And Dentistry Of New Jersey | Inhibition of hiv-1 replication by a tat rna-binding domain peptide analog |
US6043083A (en) | 1997-04-28 | 2000-03-28 | Davis; Roger J. | Inhibitors of the JNK signal transduction pathway and methods of use |
CA2290756A1 (en) | 1997-05-15 | 1998-11-19 | Cytogen Corporation | Random peptides that bind to gastro-intestinal tract (git) transport receptors and related methods |
US20040152084A1 (en) | 2003-01-31 | 2004-08-05 | Slattum Paul M. | Compounds and processes for single-pot attachment of a label to nucleic acid |
JP2002502376A (ja) | 1997-05-21 | 2002-01-22 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ | 生物学的膜を横切る輸送を増強するための組成物および方法 |
FR2767323B1 (fr) | 1997-08-12 | 2001-01-05 | Synt Em | Peptides lineaires derives de peptides antibiotiques, leur preparation et leur utilisation pour vectoriser des substances actives |
EP0897002A3 (en) | 1997-08-14 | 2001-10-04 | Smithkline Beecham Plc | U62317, a protein having a JNK-binding domain |
WO1999016787A1 (en) | 1997-09-26 | 1999-04-08 | Washington University | Cell death agonists |
US6420031B1 (en) | 1997-11-03 | 2002-07-16 | The Trustees Of Princeton University | Highly transparent non-metallic cathodes |
AU745579B2 (en) | 1997-10-20 | 2002-03-21 | F. Hoffmann-La Roche Ag | Bicyclic kinase inhibitors |
US6270956B1 (en) | 1997-12-11 | 2001-08-07 | The Salk Institute For Biological Studies | Transcriptional coactivator that interacts with Tat protein and regulates its binding to TAR RNA, methods for modulating Tat transactivation, and uses therefor |
EP0947524A1 (en) | 1998-03-30 | 1999-10-06 | Upither B.V. | Novel peptides for the treatment of autoimmune diseases |
US6248558B1 (en) | 1998-03-31 | 2001-06-19 | Vanderbilt University | Sequence and method for genetic engineering of proteins with cell membrane translocating activity |
EP1082310A4 (en) | 1998-04-29 | 2001-09-12 | Univ Georgetown | METHODS RELATING TO THE IDENTIFICATION AND USE OF COMPOUNDS THAT BIND TO HLA MOLECULES AS AGONISTS OR ANTAGONISTS TO HLA |
EP1076711A2 (en) | 1998-05-13 | 2001-02-21 | Incyte Pharmaceuticals, Inc. | Human apoptosis associated proteins |
WO1999058561A1 (fr) | 1998-05-14 | 1999-11-18 | Pasteur Merieux Serums & Vaccins | Mimotopes du virus de l'hepatite c |
US6811992B1 (en) | 1998-05-14 | 2004-11-02 | Ya Fang Liu | Method for identifying MLK inhibitors for the treatment of neurological conditions |
AU4289399A (en) | 1998-06-18 | 2000-01-05 | Dnavec Research Inc. | Nucleic acid transfer phage |
US6589503B1 (en) | 1998-06-20 | 2003-07-08 | Washington University | Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy |
AU755564B2 (en) | 1998-06-20 | 2002-12-12 | Washington University | Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy |
EP1107998B1 (en) | 1998-08-28 | 2004-02-04 | Gryphon Sciences | Method for the preparation of polyamide chains of precise length, their conjugates with proteins |
ATE361752T1 (de) | 1998-09-25 | 2007-06-15 | Cephalon Inc | Methoden zur prophylaxe und behandlung von schäden der wahrnehmungshärchenzellen und der cochlearen neuronen |
US6656474B1 (en) | 1999-01-15 | 2003-12-02 | Regeneron Pharmaceuticals, Inc. | Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders |
US6673908B1 (en) | 1999-02-22 | 2004-01-06 | Nuvelo, Inc. | Tumor necrosis factor receptor 2 |
EP1181306A4 (en) | 1999-05-28 | 2003-06-18 | Apoptosis Technology Inc | COMPOUNDS AND METHODS FOR REGULATING APOPTOSIS, AND METHODS OF MAKING AND SCREENING REGULATORY COMPOUNDS FOR APOPTOSIS |
US7510824B2 (en) | 1999-06-02 | 2009-03-31 | Nono Inc. | Method of screening peptides useful in treating traumatic injury to the brain or spinal cord |
AU5316900A (en) | 1999-06-03 | 2000-12-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) |
DK1102785T3 (da) | 1999-06-07 | 2013-05-13 | Arrowhead Res Corp | Sammensætninger til lægemiddeltilførsel ved anvendelse af pH-følsomme molekyler |
US6669951B2 (en) | 1999-08-24 | 2003-12-30 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
EP1210121A2 (en) | 1999-08-24 | 2002-06-05 | Cellgate Inc. | Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties |
EP1210362A2 (en) | 1999-09-01 | 2002-06-05 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, dna and viruses |
US20030104622A1 (en) | 1999-09-01 | 2003-06-05 | Robbins Paul D. | Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses |
US20040082509A1 (en) | 1999-10-12 | 2004-04-29 | Christophe Bonny | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
US8183339B1 (en) | 1999-10-12 | 2012-05-22 | Xigen S.A. | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
US20010046489A1 (en) | 1999-12-06 | 2001-11-29 | Habener Joel E. | Stem cells of the islets of langerhans and their use in treating diabetes mellitus |
US6586403B1 (en) | 2000-07-20 | 2003-07-01 | Salpep Biotechnology, Inc. | Treating allergic reactions and inflammatory responses with tri-and dipeptides |
US6897231B2 (en) | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
JP4387669B2 (ja) | 2000-10-13 | 2009-12-16 | ザイジェン エス.アー. | 新規なトランスポーターペプチド配列による生物学的エフェクターの細胞内送達 |
US7033597B2 (en) | 2000-10-13 | 2006-04-25 | Université de Lausanne | Intracellular delivery of biological effectors |
AU1112202A (en) | 2000-10-17 | 2002-04-29 | Diatranz Ltd | Preparation and xenotransplantation or porcine islets |
CA2437248A1 (en) | 2001-02-02 | 2002-08-15 | Takeda Chemical Industries, Ltd. | Jnk inhibitor |
US20030077826A1 (en) | 2001-02-02 | 2003-04-24 | Lena Edelman | Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC) |
US20030091640A1 (en) | 2001-02-08 | 2003-05-15 | Srinivasan Ramanathan | Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents |
JP2005508832A (ja) | 2001-02-16 | 2005-04-07 | セルゲイト, インコーポレイテッド | 間隔を開けてアルギニン部分を含むトランスポーター |
DE10117281A1 (de) | 2001-04-06 | 2002-10-24 | Inst Molekulare Biotechnologie | Peptid zur Diagnose und Therapie der Alzheimer-Demenz |
WO2002081504A2 (en) | 2001-04-06 | 2002-10-17 | Thomas Jefferson University | Multimerization of hiv-1 vif protein as a therapeutic target |
WO2003008553A2 (en) | 2001-07-17 | 2003-01-30 | Incyte Genomics, Inc. | Proteins associated with cell growth, differentiation, and death |
WO2004045535A2 (en) | 2002-11-14 | 2004-06-03 | Arbor Vita Corporation | Molecular interactions in neurons |
IL160915A0 (en) | 2001-09-19 | 2004-08-31 | Aventis Pharma Sa | Indolizines inhibiting kinase proteins |
JP2005525096A (ja) | 2002-01-09 | 2005-08-25 | ユニバーシティ オブ ローザンヌ | Jnkシグナル伝達経路の細胞浸透性ペプチドインヒビター |
CA2478338A1 (en) | 2002-03-08 | 2003-09-18 | Signal Pharmaceuticals, Inc. | Combination therapy for treating, preventing or managing proliferative disorders and cancers |
SE0201863D0 (en) | 2002-06-18 | 2002-06-18 | Cepep Ab | Cell penetrating peptides |
AU2003267124A1 (en) | 2002-09-09 | 2004-03-29 | Dana-Farber Cancer Institute, Inc. | Bh3 peptides and method of use thereof |
PL374700A1 (en) | 2002-09-20 | 2005-10-31 | Alcon, Inc. | Use of cytokine synthesis inhibitors for the treatment of dry eye disorders |
ATE350480T1 (de) | 2002-10-11 | 2007-01-15 | Imvision Gmbh | Moduläre antigen-transporter moleküle (mat- moleküle) zur modulierung von immunreaktionen, zugehörige konstrukte, verfahren und verwendungen |
WO2004037196A2 (en) | 2002-10-24 | 2004-05-06 | Sangstat Medical Corporation | Cytomodulating peptides and methods for treating neurological disorders |
BR0316256A (pt) | 2002-11-18 | 2005-10-04 | Celgene Corp | Métodos de inibir a produção de tnf-alfa e a atividade de pde4, de tratar ou prevenir uma doença ou um distúrbio, de controlar os nìveis de camp em uma célula e de produzir um composto, composição farmacêutica e composto |
US20050019366A1 (en) | 2002-12-31 | 2005-01-27 | Zeldis Jerome B. | Drug-coated stents and methods of use therefor |
US7166692B2 (en) | 2003-03-04 | 2007-01-23 | Canbrex Bio Science Walkersville, Inc. | Intracellular delivery of small molecules, proteins, and nucleic acids |
EP2295433A3 (en) | 2003-03-06 | 2011-07-06 | Eisai R&D Management Co., Ltd. | JNK inhibitors |
WO2004092339A2 (en) | 2003-04-11 | 2004-10-28 | Ilex Products, Inc. | Modulation of muc1 mediated signal transduction |
AU2004235396B2 (en) | 2003-04-29 | 2010-11-25 | Sarepta Therapeutics, Inc. | Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells |
US20060222657A1 (en) | 2003-06-20 | 2006-10-05 | Dowdy Steven F | Polypeptide transduction and fusogenic peptides |
KR100685345B1 (ko) | 2004-03-27 | 2007-02-22 | 학교법인조선대학교 | 세포사 유도 펩타이드 |
US20080039377A1 (en) | 2004-04-08 | 2008-02-14 | Applied Research Systems Ars Holding N.V. | Composition Comprising a Jnk Inhibitor and Cyclosporin |
EP1786781A2 (en) | 2004-08-27 | 2007-05-23 | GPC Biotech AG | Pyrimidine derivatives |
US20060094753A1 (en) | 2004-10-29 | 2006-05-04 | Alcon, Inc. | Use of inhibitors of Jun N-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases |
EP1656951A1 (en) | 2004-11-12 | 2006-05-17 | Xigen S.A. | Conjugates with enhanced cell uptake activity |
EP1676574A3 (en) | 2004-12-30 | 2006-07-26 | Johnson & Johnson Vision Care, Inc. | Methods for promoting survival of transplanted tissues and cells |
US20060223807A1 (en) | 2005-03-29 | 2006-10-05 | University Of Massachusetts Medical School, A Massachusetts Corporation | Therapeutic methods for type I diabetes |
US20060258706A1 (en) | 2005-04-29 | 2006-11-16 | Manohar Saindane | Solid forms of a JNK inhibitor |
US20070015779A1 (en) | 2005-04-29 | 2007-01-18 | John Griffin | Compositions and treatments for inhibiting kinase and/or hmg-coa reductase |
US20070003531A1 (en) | 2005-06-30 | 2007-01-04 | University Of Connecticut | Methods for improving immunotherapy by enhancing survival of antigen-specific cytotoxic T lymphocytes |
US8080517B2 (en) | 2005-09-12 | 2011-12-20 | Xigen Sa | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
WO2007031098A1 (en) | 2005-09-12 | 2007-03-22 | Xigen S.A. | Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
WO2008006046A1 (en) | 2006-07-06 | 2008-01-10 | Case Western Reserve University | Ceramide composition and use thereof in treatment of ocular diseases |
WO2008094208A2 (en) | 2006-08-02 | 2008-08-07 | Northwestern University | Protein kinase targeted therapeutics |
AU2007293917B2 (en) | 2006-09-08 | 2013-01-31 | F. Hoffmann-La Roche Ag | Benzotriazole kinase modulators |
CA2663545A1 (en) * | 2006-09-19 | 2008-03-27 | Phylogica Limited | Neuroprotective peptide inhibitors of ap-1 signaling and uses thereof |
GB0702259D0 (en) | 2007-02-06 | 2007-03-14 | Eisai London Res Lab Ltd | 7-azaindole derivatives |
RU2510274C2 (ru) | 2008-05-07 | 2014-03-27 | Дзе Реджентс Оф Дзе Юниверсити Оф Калифорния | Терапевтическое восстановление и усиление увлажнения поверхности глаза |
WO2009143865A1 (en) | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
WO2009143864A1 (en) | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases |
US20100183633A1 (en) | 2008-12-04 | 2010-07-22 | University Of Massachusetts | Interleukin 6 and tumor necrosis factor alpha as biomarkers of jnk inhibition |
KR20120022721A (ko) | 2009-03-30 | 2012-03-12 | 산텐 세이야꾸 가부시키가이샤 | JNK(c-Jun 아미노 말단 키나제) 저해 펩티드를 이용한 망막 질환의 예방 또는 치료제, 망막 질환의 예방 또는 치료 방법, 및 이 펩티드의 용도 |
WO2011160653A1 (en) | 2010-06-21 | 2011-12-29 | Xigen S.A. | Novel jnk inhibitor molecules |
PL2902035T3 (pl) | 2010-10-14 | 2019-04-30 | Xigen Inflammation Ltd | Przechodzące przez komórkę peptydowe inhibitory szlaku przekazywania sygnałów przez JNK do zastosowania w leczeniu chorób zapalnych oka |
WO2012048721A1 (en) | 2010-10-14 | 2012-04-19 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases |
US8471027B2 (en) | 2011-04-06 | 2013-06-25 | Hoffmann-La Roche Inc. | Adamantyl compounds |
WO2013091670A1 (en) | 2011-12-21 | 2013-06-27 | Xigen S.A. | Novel jnk inhibitor molecules for treatment of various diseases |
WO2014206426A1 (en) | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
-
2005
- 2005-09-12 WO PCT/EP2005/009782 patent/WO2007031098A1/en active Application Filing
-
2006
- 2006-09-12 CN CN2006800333412A patent/CN101263157B/zh active Active
- 2006-09-12 ES ES06792004T patent/ES2388076T3/es active Active
- 2006-09-12 CA CA2621337A patent/CA2621337C/en active Active
- 2006-09-12 UA UAA200804223A patent/UA98101C2/ru unknown
- 2006-09-12 US US12/066,657 patent/US8748395B2/en active Active
- 2006-09-12 DK DK06792004.1T patent/DK1928903T3/da active
- 2006-09-12 ZA ZA200800848A patent/ZA200800848B/xx unknown
- 2006-09-12 RS RS20160222A patent/RS54701B1/en unknown
- 2006-09-12 EP EP11003985.6A patent/EP2418217B1/en active Active
- 2006-09-12 RS RS20120310A patent/RS52379B/en unknown
- 2006-09-12 EP EP06792004A patent/EP1928903B1/en active Active
- 2006-09-12 DK DK11003985.6T patent/DK2418217T3/en active
- 2006-09-12 SI SI200631345T patent/SI1928903T1/sl unknown
- 2006-09-12 PL PL06792004T patent/PL1928903T3/pl unknown
- 2006-09-12 BR BRPI0616824A patent/BRPI0616824B8/pt active IP Right Grant
- 2006-09-12 SI SI200632044A patent/SI2418217T1/sl unknown
- 2006-09-12 PL PL11003985T patent/PL2418217T4/pl unknown
- 2006-09-12 KR KR1020087006094A patent/KR101305533B1/ko active IP Right Grant
- 2006-09-12 ES ES11003985.6T patent/ES2567708T3/es active Active
- 2006-09-12 PT PT06792004T patent/PT1928903E/pt unknown
- 2006-09-12 HU HUE11003985A patent/HUE029132T2/en unknown
- 2006-09-12 ME MEP-2016-62A patent/ME02426B/me unknown
- 2006-09-12 JP JP2008530405A patent/JP5386169B2/ja active Active
- 2006-09-12 EP EP15002528.6A patent/EP3012266A1/en not_active Withdrawn
- 2006-09-12 ME MEP-2014-123A patent/ME02000B/me unknown
- 2006-09-12 EA EA200800680A patent/EA014330B1/ru not_active IP Right Cessation
- 2006-09-12 WO PCT/EP2006/008882 patent/WO2007031280A2/en active Application Filing
- 2006-09-12 AU AU2006291541A patent/AU2006291541B2/en active Active
-
2008
- 2008-01-30 IL IL189133A patent/IL189133A/en active IP Right Grant
- 2008-04-04 NO NO20081664A patent/NO342272B1/no not_active IP Right Cessation
- 2008-11-26 HK HK08112945.3A patent/HK1118841A1/xx unknown
-
2012
- 2012-01-05 JP JP2012000381A patent/JP5727393B2/ja active Active
- 2012-05-08 HK HK12104474.3A patent/HK1163712A1/zh unknown
- 2012-07-04 CY CY20121100593T patent/CY1112924T1/el unknown
- 2012-07-19 HR HRP20120598TT patent/HRP20120598T1/hr unknown
-
2013
- 2013-12-31 US US14/144,938 patent/US9290538B2/en active Active
-
2014
- 2014-10-23 JP JP2014216270A patent/JP2015034171A/ja not_active Withdrawn
-
2015
- 2015-03-26 IL IL237984A patent/IL237984A0/en unknown
-
2016
- 2016-02-16 US US15/045,058 patent/US20160264630A1/en not_active Abandoned
- 2016-04-11 CY CY20161100290T patent/CY1117351T1/el unknown
- 2016-04-12 HR HRP20160379TT patent/HRP20160379T1/hr unknown
- 2016-10-24 HK HK16112196.9A patent/HK1223948A1/zh unknown
-
2017
- 2017-06-21 US US15/628,771 patent/US20170320917A1/en not_active Abandoned
-
2019
- 2019-07-29 US US16/525,234 patent/US20200062805A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003511071A (ja) * | 1999-10-12 | 2003-03-25 | ユニバーシティ オブ ローザンヌ | Jnkシグナル導入経路の細胞透過性ペプチドインヒビター |
WO2003103698A1 (en) * | 2002-06-07 | 2003-12-18 | University Of Lausanne | Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
Non-Patent Citations (4)
Title |
---|
JPN6011034654; Diabetes Vol.50, No.1, 2001, pp.77-82 * |
JPN6011034657; J. Biol. Chem. Vol.277, No.13, 2002, pp.10987-10997 * |
JPN6012051332; Stroke Vol.35, No.7, 2004, pp.1738-1743 * |
JPN6012051333; International Journal of Oncology Vol.25, No.6, 2004, pp.1721-1727 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5727393B2 (ja) | Jnkシグナル伝達経路の細胞透過性ペプチド阻害剤 | |
US8080517B2 (en) | Cell-permeable peptide inhibitors of the JNK signal transduction pathway | |
JP5490343B2 (ja) | Jnkシグナル導入経路の細胞透過性ペプチドインヒビター | |
JP5824085B2 (ja) | Jnkシグナル伝達経路に対する、細胞透過性のペプチド性阻害剤の種々の、疾病を治療するための使用 | |
EP1776958B9 (en) | Cell-permeable peptide inhibitors of the JNK signal transduction pathway | |
JP2005525096A (ja) | Jnkシグナル伝達経路の細胞浸透性ペプチドインヒビター | |
AU2012203529B2 (en) | Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130903 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20131202 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131205 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20131211 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140124 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140819 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141023 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20150106 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150310 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150402 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5727393 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |